☆ 4.2 Meeting Abstract

Phase 1 Study of CA-4948, a Novel Inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in Patients with R/R Non-Hodgkin Lymphoma (NHL)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Volume 19, Issue -, Pages S256-S257

Publisher

CIG MEDIA GROUP, LP

DOI: 10.1016/j.clml.2019.07.168

Keywords

ABCL; aggressive B-cell lymphoma; IRAK4; MYD88; DLBCL; TLR; NHL

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.